The syntheses of 5-fluoro (FaraU) and (E)-5-(2-fluorovinyl) arabinosyl uridine (FVAU) via 5-trimethylstannyl and (E)-5-(2-tributylstannylvinyl) arabinosyl uridine analogues with selectfluor is described. Boc protection of the uridine moiety improved the yield of synthesis and differences between N-Boc and O-Boc isomers were established by 1 H-and 13 C NMR. The Boc-protected stannyl intermediates may be fluorinated with 18 F to produce [ 18 F]FaraU and [ 18 F]FVAU.
There is an increasing demand for radiofluoro-labeled nucleosides that can be used for imaging herpes simplex virus thymidine kinase (HSV-1 TK) transfected cancerous cells in cancer gene therapy research. 1 In these approaches, the cancer lesion is first marked by the HSV-1 TK encoded gene, followed by the introduction of a non-toxic prodrug, which is commonly a nucleoside analogue. After entering the intracellular milieu, the prodrug can be phosphorylated by cellular enzymes to form a toxic metabolite capable of causing premature termination of DNA replication, through a suicide mechanism. 2 To achieve an optimal therapeutic effect, however, localizing where this event occurs using a tagged nucleoside analogue is necessary. Such an assessment of gene expression levels of HSV-1 TK in animal studies has been successfully quantified using positron emission tomography (PET). 3, 4 Among the positron emitters used, 18 F is a typical choice for PET applications since it has an adequate half-life of 110 minutes and a high positron content: 99% b + for one decay. So far, several compounds, including [ 18 F]FHBG and [ 124 I]FIAU, have been developed and used as powerful tools in PET studies ( Figure 1 ). 5, 6 Fluoro and fluorovinyl groups represent one class of substituents with which to modify nucleoside bioactivities against various diseases such as HSV infection and cancers. 7 While the syntheses of 5-fluoro (FaraU) and 5-fluorovinyl arabinosyl uridines (FVAU) were first reported a decade ago, there have been relatively few subsequent studies undertaken. 8 This may due to a number of factors such as the tedious manipulation and extensive purification procedures involved. A survey of the literature shows that there are two predominant methods that have been used for the synthesis of 5-fluorovinyl uridine. Both meth-ods involve multiple steps. One approach includes the introduction of alpha-fluoro ethyl acetate onto the 5methylene of 5-bromomethyl uridine, a UV-induced incorporation of bromine onto 5-methylene, base-induced elimination of HBr and final treatment with a cation exchange resin at high temperature to eliminate carbon dioxide. The second approach employs a similar strategy using sodium hydride, purification using ethyl acetate and sodium hydroxide on silica gel and final acid-induced decarboxylation.
Compared
with 5-(2-bromovinyl)-2¢-deoxyuridine (BVDU), which is one of the most potent inhibitors of HSV-1 TK, its fluoro counterpart, FVDU, is ten-fold less effective. 9 This characteristic does, however, make 5-(2fluorovinyl)arabinosyl uridine (FVAU) suitable for in vivo studies. It should be noted that the 2¢-hydroxy group with 'up' configuration is crucial in maintaining both stability and bioactivity in vivo. 10 In order to prepare 18 Flabeled arabinosyl uridine, a practical syntheses of the nonradioactive FaraU and FVAU first needed to be developed. As part of our systematic syntheses of radiolabeled thymidine analogues, 11 we wish to report here the preparation of FaraU and FVAU via fluorodestannylation with Selectfluor, a common fluorinating reagent. 12, 13 Preparation of 5-trimethystannyl arabinosyl uridine 4 could be readily achieved through a published procedure 11f (Scheme 1) and subsequent fluorination afforded the protected fluorinated product 5 in 30% yield. After deprotection, a satisfactory yield of FaraU 6 was obtained, which could be used as an authentic sample. However, as our previous report on the radiofluorination of stannylvinyl uridine analogue with [ 18 F]F 2 indicated, the proton at N-3 was prone to substitution by fluorine, leading to a labile N-F bond, which was eventually reprotonated. 11d This process led to the formation of [ 18 F]HF which was no longer capable of serving as an electrophilic fluorine with which to replace stannane, resulting in poor radiochemical yield. In order to overcome this drawback, the nitrogen at N-3 was protected as its butoxycarbonylamide (Boc). This modified tin precursor 3a, when fluorinated under the conditions described above, improved the yield of fluorinated product 7 to 50%. Subsequent removal of the Boc group, unlike that of the relatively stable tolyl group, 14 was trivial. Interestingly, the Boc group tended to migrate during its introduction and the subsequent stannylation (Schemes 2 and 3). The distinction between O-substituted (2b, 3b and 3c) and N-substituted isomers (2a and 3a) could be made through 13 C NMR: a down-field shift of about 85 ppm was observed for the O-substituted tertiary carbon of Boc, compared to that of the N-substituted isomer. Furthermore, in contrast to the clear carbonyl carbon signal arising from the Boc group of 3b at 163 ppm, only very weak or even no corresponding signals for 2a, 3a or 3c were detected. By adopting a similar synthetic approach to that described above, tin compounds 10 and 11 were obtained in excellent yields (Scheme 4). Both the fluoro nucleosides 12 and 14 could be obtained in limited yields after fluorination, with the E-isomer of both compounds being unambiguously assigned by 1 H, 13 C and 19 F NMR. Interestingly, in contrast to products obtained using F 2 , where a ratio of Eand Z-isomers of 2:1 was observed, 11d in this approach, none of the Z-isomer was detected. Furthermore, the proposed Pd-mediated migration of Boc during stannylation discussed above, apparently did not take place in this case since no isomers of 5-(2-stannanyl)vinyl counterparts 10 were detected either by TLC or after column chromatography. This might be due to the relative inertness of the Boc group towards radical-catalyzed stannylation. In conclusion, practical syntheses of FaraU 6 and FVAU 13 have been developed. Though the limited yield of FVAU 13 seems far below that required for mass production, our yields of the final products are still sufficient for both bioscreening studies and radiofluorination experiments. Furthermore, we have found that the use of Bocprotected tin precursors 3a, 3b, 3c and 10 is crucial for the efficient production of 18 Electrospray mass spectra were measured on a quadropole mass spectrometer equipped with an electrospray source (MICROMASS Waters 600S). NMR spectra were recorded with a Varian Unity Inova spectrometer operating at 500 MHz ( 1 H NMR) or 125.7 MHz ( 13 C NMR). Analytical thin-layer chromatography (TLC) was performed on silica gel 60 F254. TLC monitoring was performed by staining with p-anisaldehyde and by UV at 254 nm. Flash column chromatography was performed with Merck Geduran Si 60 (230-400 mesh). Eluents EtOAc, acetone and n-hexane were freshly distilled for column chromatography. Normal-phase HPLC (Agilent 1100) was equipped with a sample loop (500 mL) and a semipreparative column (9.4 × 250 mm ZORBAX SIL, 5 mm material). Constant conditions were used: flow rate of 3 mL/min; detection, UV (260 nm). RP-HPLC (Agilent 1100) was equipped with a semipreparative column (Astec, 10 × 250 mm, C18, 5 mm material). Isocratic conditions were used: mobile phase MeOH-H 2 O 3:7; flow rate of 3 mL/min; detection, UV (260 nm). All retention times are quoted in minutes. Acetonitrile and toluene were dried by refluxing over calcium hydride. THF was dried by refluxing over sodium. MeOH was dried by refluxing over magnesium. Chemicals were obtained commercially and used in all experiments without purification.
3-N-Boc-5-iodo-2¢,3¢,5¢-tri-O-acetyl Arabinosyl Uridine (2a) and 2b
Compound 1 (500 mg, 1.00 mmol) and (Boc) 2 O (327 mg, 1.50 mmol) were stirred in THF (7 mL) at r.t. for 80 min. DMAP (1.3 mmol, 160 mg) was added to the reaction mixture and the reaction was allowed to proceed for a further 4 h until product 2 was formed and the starting material 1 (R f = 0.19; EtOAc-n-hexane, 1:1) was consumed. After removal of the volatile solvents, EtOAc (30 mL) was added and sequentially washed with H 2 O (10 mL), HCl (1 N, 5 mL), and aq NaHCO 3 (sat., 10 mL). The organic layer was then dried (Na 2 SO 4 ), evaporated and purified by column chromatography on silica gel (EtOAc-n-hexane, 1:3) to give 2a and 2b. 
3-N-Boc-5-trimethylstannyl-2¢,3¢,5¢-tri-O-acetyl Arabinosyl Uridine 3a-c
Compound 2a (170 mg, 0.285 mmol), hexamethylditin (165 mg, 0.5 mmol), bis(triphenylphosphine)palladium dichloride (5 mg, 8 mmol), and 1,4-dioxane (10 mL) were stirred at 80°C for 2 h to give a mixture of compounds 3a-c (monitored by TLC). Upon completion, the solvent was removed at 45°C under reduced pressure and the residue was purified by column chromatography (n-hexane-EtOAc, 1:4) to provide a mixture of 3 in 30% overall yield (60 mg). Further purification with normal-phase HPLC separated the three isomers in a ratio of 1:1:1. The HPLC (Agillent 1100) was equipped with a sample loop (500 mL), a semipreparative column (ZORBAX SIL, 9.4 × 250 mm, 5 mm) and was eluted with n-hexane-EtOAc (3:1), flow rate: 3 mL/min and UV detector setting at 254 nm. 
5-Fluoro-2¢,3¢,5¢-tri-O-acetyl Arabinosyl Uridine (5)
To a dried round-bottomed flask (25 mL), compound 4 (100mg, 0.19 mmol), MeCN (15 mL) and Selectfluor (69 mg, 0.20 mmol) were added. The mixture was stirred at 55°C for 10 h, during which the progress of the reaction was followed by TLC, until the starting material 4 [R f = 0.78 (n-hexane-acetone, 1:1)] had been consumed (~10 h). The solvent was removed and the crude mixture was purified by column chromatography (n-hexane-EtOAc, 3:2). 
3-N-Boc-5-ethynyl-2¢,3¢,5¢-tri-O-acetyl Arabinosyl Uridine (9)
Compound 8 (569 mg, 1.4 mmol), (Boc) 2 O (1.1 mL, 4.9 mmol) and THF (30 mL) were stirred at 80°C for 5 min. The solution was allowed to come to r.t. then DMAP (176 mg, 1.44 mmol) was added and the mixture was stirred for 4 h [reaction monitored by TLC ( n-
